Our study reveals the potential therapeutic role of dual inhibition of CDK4/6 and PI3K/mTOR pathways in iCCA, and proposes a new paradigm for the clinical treatment of iCCA. This evidence concerns the gene MTOR and infantile convulsions and choreoathetosis.